| PISON, Christophe |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
| Pépin, Jean-Louis JP |
keePaOSA, NCT04875897: Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea |
|
|
| Not yet recruiting | N/A | 65 | NA | keepMED PAP device | keepMED Ltd., CRI-The Clinical Research Institute GmbH | Obstructive Sleep Apnea | 01/22 | 02/22 | | |
NCT05698602: Safety and Performance of NivolisMonitor and NivolisAnton for Monitoring Patients on Ventilatory Assistance at Home |
|
|
| Active, not recruiting | N/A | 10 | Europe | NivolisMonitor, NivolisAnton | VIVARDIS | Respiratory Insufficiency, Respiratory Failure, Home Monitoring | 07/25 | 12/25 | | |
| Not yet recruiting | N/A | 176 | Europe | PWV measurement | Withings | Vascular Stiffness | 05/24 | 11/24 | | |
| Not yet recruiting | N/A | 10000 | NA | Nutritional Psycho-Behavioral Reeducation Program, RNPC Program | Groupe Éthique et Santé, University Grenoble Alps, Novo Nordisk A/S, Lyon Est University | Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2, Sleep Apnea, Obstructive, NAFLD, NASH | 07/30 | 07/30 | | |
| PEPIN, Jean-Louis JL |
AT1Home, NCT02796534: Prevalence of Obstructive Sleep Apnea Syndrome in Type 1 Diabetic Patients Treated With Insulin Pump (At1Home) |
|
|
| Completed | N/A | 825 | Europe | Diagnosis of sleep apnea by oxymetry | University Hospital, Grenoble, VitalAire, ResMed | Type 1 Diabetes | 07/18 | 03/23 | | |
CONNECTOSOM, NCT04777799: Effectiveness and Acceptability of a Digital Solution to Train Specific EEG Frequencies With Neurofeedback for Improving Sleep |
|
|
| Terminated | N/A | 14 | Europe | URGOnight | AdministrateurDRC, Urgotech, University Hospital, Grenoble | Insomnia, Sleep Disorder | 06/22 | 06/22 | | |
OLIGO-SAS, NCT05758324: Study Evaluating the Effect of a Specific Trace Metal Complex Versus Placebo on the Severity of Apnea in Patients With Obstructive Sleep Apnea Syndrome |
|
|
| Not yet recruiting | N/A | 42 | Europe | Nutri PNEA, Placebo | Laboratoires Pronutri, Clin-Experts | Apnea, Obstructive | 01/24 | 01/24 | | |
SUNSAS, NCT05057975: Validation of an Integrated Digital Solution (SUNrise®) Versus Polysomnography for Obstructive Sleep Apnea Diagnosis |
|
|
| Completed | N/A | 848 | Europe | Sunrise, polysomnography | Sunrise, ICUREsearch | Obstructive Sleep Apnea | 10/24 | 10/24 | | |
| PEPIN, Jean Louis |
| Recruiting | N/A | 400 | Europe | CPAP, MAD | ResMed | OSA | 10/22 | 10/26 | | |
| Tamisier, Renaud |
| Completed | N/A | 7 | Europe | Activated Inspire® Upper Airway Stimulation System, Inactivated Inspire® Upper Airway Stimulation System | University Hospital, Grenoble, Inspire Medical Systems, Inc. | Obstructive Sleep Apnea Syndrome | 12/21 | 10/23 | | |
SUNSAS, NCT05057975: Validation of an Integrated Digital Solution (SUNrise®) Versus Polysomnography for Obstructive Sleep Apnea Diagnosis |
|
|
| Completed | N/A | 848 | Europe | Sunrise, polysomnography | Sunrise, ICUREsearch | Obstructive Sleep Apnea | 10/24 | 10/24 | | |
| Recruiting | N/A | 70 | Europe | Deem 3 Headband | University Hospital, Grenoble, Dreem, AGIR à Dom | Sleep Apnea, Obstructive Sleep Apnea | 11/25 | 12/25 | | |
| Recruiting | N/A | 400 | Europe | CPAP, MAD | ResMed | OSA | 10/22 | 10/26 | | |
| Detante, Olivier |
| Not yet recruiting | 2 | 60 | Europe | OTR4132, Placebo | Organ, Tissue, Regeneration, Repair and Replacement, Euraxi Pharma | Endovascular Thrombectomy, Ischemic Cerebrovascular Accident | 03/26 | 03/26 | | |
| Recruiting | N/A | 52 | Europe | Hippotherapy, Conventional Neurorehabilitation | Alliance Equiphoria, Boehringer Ingelheim, Centre Hospitalier Sud Francilien, Centre Hospitalier de Béziers, University Hospital, Grenoble | Cerebrovascular Accident, Neurorehabilitation, Neuroplasticity, Hippotherapy, Silent Neurofunctional Barriers, Functional Deficit, Cognitive Deficit, Psychological Trauma, Autonomy, Quality of Life, Caregiver Burnout | 11/25 | 03/26 | | |
MATRISS, NCT04083001: An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS) |
|
|
| Completed | N/A | 19 | Europe | OTR4132MD | Organ, Tissue, Regeneration, Repair and Replacement, European Commission, Euraxi Pharma | Stroke, Acute | 06/24 | 06/24 | | |
| PIN, Isabelle |
| Recruiting | N/A | 160 | Europe | SIMEOX | Physio-Assist, Icadom | Pulmonary Cystic Fibrosis | 12/24 | 06/25 | | |
| Bouzat, Pierre |
T-STORHM, NCT04431999: Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage |
|
|
| Recruiting | 3 | 200 | Europe | Whole blood transfusion, Fractionated blood products transfusion | Direction Centrale du Service de Santé des Armées, TIMC-IMAG, Floralis | Trauma, Acute Hemorrhage, Coagulopathy | 09/24 | 09/25 | | |
| gauvrit, jean-yves |
| Recruiting | N/A | 119 | Europe | Implantation of an eCLIPs™ device, eCLIPs™ Electrolytic Bifurcation Systems | Evasc Medical Systems Corp., European Cardiovascular Research Center | Intracranial Aneurysm | 04/25 | 04/26 | | |
| LEROY, Vincent |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
DHELIVER, NCT04229901: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) |
|
|
| Terminated | 2 | 133 | Europe, RoW | HepaStem, Placebo | Cellaion SA | Acute on Chronic Liver Failure | 05/24 | 05/24 | | |
| Active, not recruiting | 2 | 72 | Europe, RoW | Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate | Intercept Pharmaceuticals | Primary Biliary Cholangitis | 10/25 | 10/25 | | |
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy |
|
|
| Active, not recruiting | 2 | 184 | Europe, RoW | GSK3228836, Bepirovirsen, GSK3528869A, Control | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 02/26 | 02/26 | | |
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection |
|
|
| Terminated | 1/2 | 135 | Europe, RoW | ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 10/24 | 10/24 | | |
| Bourdat-Michel, Guylhène |
| Not yet recruiting | 2/3 | 72 | Europe | ADV7103, Placebo | Advicenne Pharma | Cystinuria | 05/25 | 06/25 | | |
| Laurent, Valérie |
SEPT9-CROSS, NCT03311152: Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis |
|
|
| Completed | N/A | 529 | Europe | "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany), Plasma mSEPT9 test | Central Hospital, Nancy, France, Institut National de la Santé Et de la Recherche Médicale, France, Groupement Interrégional de Recherche Clinique et d'Innovation, Epigenomics, Inc, New Day Diagnostics | Hepatocellular Carcinoma, Cirrhosis | 10/24 | 10/24 | | |
| Vanzetto, Gerald |
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease |
|
|
| Terminated | 3 | 874 | Europe | OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od | University Hospital, Brest, Bayer | Coronary Artery Disease | 10/24 | 10/24 | | |
| Sengel, Christian |
PROACTIF, NCT04069468: Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) |
|
|
| Completed | N/A | 1247 | Europe | TheraSphere, Yttrium-90 Glass Microspheres | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| MAINDET, Caroline |
CAPNEUCHIM, NCT05840562: Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy |
|
|
| Recruiting | 3 | 274 | Europe | Capsaicin, Qutenza, Duloxetine, Cymbalta | Institut Cancerologie de l'Ouest, Grünenthal GmbH | Chemotherapy-induced Peripheral Neuropathy | 03/27 | 03/27 | | |
EPIKARD, NCT03889288: Innovative Device for Pain Management by Millimeter Band Radiation: Electronic-Pain Killer |
|
|
| Recruiting | N/A | 110 | Europe | Medical device - electronic-pain killer | University Hospital, Grenoble, Remedee SA, Clinical Investigation Centre for Innovative Technology Network | Aortic Valve Replacement | 01/22 | 01/22 | | |
| Completed | N/A | 170 | Europe | Immediate Remedee Solution, Delayed Remedee Solution | Remedee SA | Fibromyalgia | 07/22 | 02/23 | | |
| Completed | N/A | 60 | Europe | Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation | University Hospital, Grenoble, Remedee SA, Clinical Investigation Centre for Innovative Technology Network | Osteoarthritis, Peripheral, Pain | 08/22 | 08/22 | | |
| Completed | N/A | 140 | Europe | Wristband with millimeter wave emission., Placebo of wristband with millimeter wave emission. | Remedee SA | Migraine Without Aura | 10/22 | 01/23 | | |
| Barone-Rochette, Gilles |
IC-HOT-MICRO, NCT05790876: Super Saturated Oxygen (SSO2) Therapy in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Action on Coronary Microcirculation Dysfunction |
|
|
| Not yet recruiting | N/A | 10 | Europe | SSO2 therapy | University Hospital, Grenoble, Zoll Medical Corporation | STEMI, Coronary Microvascular Dysfunction | 03/24 | 06/24 | | |
| ROTH, Gaël |
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. |
|
|
| Active, not recruiting | 2 | 307 | Europe | Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Metastatic Pancreatic Adenocarcinoma | 07/23 | 12/24 | | |
ABE-LIVER, NCT05448677: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma |
|
|
| Terminated | 2 | 3 | Europe | Ezurpimtrostat, Atezolizumab, Bevacizumab | University Hospital, Grenoble, Genoscience Pharma | Hepatocellular Carcinoma | 03/24 | 03/24 | | |
Liver-NET1, NCT05546879: Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC |
|
|
| Recruiting | 1 | 52 | Europe | NP137, Atezolizumab, Bevacizumab | University Hospital, Grenoble, NETRIS Pharma | Hepatocellular Carcinoma | 03/26 | 03/27 | | |
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Active, not recruiting | 1 | 52 | Europe | NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU | University Hospital, Grenoble, NETRIS Pharma | Pancreatic Ductal Adenocarcinoma | 03/26 | 03/27 | | |
| GRANGE, Laurent |
LOMBACT, NCT04701073: Lumbar Belt Benefit Compared to the Usual Care in the Treatment of Non-specific Low Back Pain |
|
|
| Completed | N/A | 168 | Europe | LombaStab belt | Thuasne, RCTs | Low Back Pain | 06/24 | 06/24 | | |
| PHD, Gaël ROTH MD |
ABE-LIVER, NCT05448677: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma |
|
|
| Terminated | 2 | 3 | Europe | Ezurpimtrostat, Atezolizumab, Bevacizumab | University Hospital, Grenoble, Genoscience Pharma | Hepatocellular Carcinoma | 03/24 | 03/24 | | |
